| 摘要 |
PROBLEM TO BE SOLVED: To provide an atrial remodeling inhibitor for prophylaxis and therapy of chronic atrial fibrillation, wherein Kv1.5 protein that is an ion channel is reduced to make an antiarrhythmic drug ineffective by the atrial remodeling. SOLUTION: The atrial remodeling inhibitor includes EPA (eicosapentaenoic acid) in a low dose for increasing the Kv1.5 protein in cardiac muscle, wherein the EPA is orally and chronically administered to a patient. The atrial remodeling inhibitor can prevent even a decrease in cardiac contractility, thrombus, embolism, or cerebral apoplexy etc., caused by the atrial fibrillation. COPYRIGHT: (C)2010,JPO&INPIT |
